A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile.
about
Obesity: Current and potential pharmacotherapeutics and targets.Intestine-specific Mttp deletion decreases mortality and prevents sepsis-induced intestinal injury in a murine model of Pseudomonas aeruginosa pneumoniaIntestine-Specific Mttp Deletion Increases the Severity of Experimental Colitis and Leads to Greater Tumor Burden in a Model of Colitis Associated Cancer.The chylomicron: relationship to atherosclerosis.Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.Inhibition of cholesterol absorption: targeting the intestine.Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition.An overview of the new frontiers in the treatment of atherogenic dyslipidemias.Investigational therapies for the treatment of atherosclerosis.Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.Looking into the crystal ball-upcoming drugs for dyslipidemia.The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: risks, benefits, and management.Emerging pathways in the regulation of whole body cholesterol flux: therapeutic opportunities to target atherosclerosis?Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia.Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing.
P2860
Q30243992-E84622A1-84D5-413C-BB14-2D778E1898B7Q34474151-C4C3DEFE-9835-47FE-AC4E-C7B7D21B2277Q34785759-81F3CE9C-161F-4AFF-88E9-0CB49E1BABE3Q35295065-06791C95-E96B-452E-9E92-2CA56A428882Q37172133-FBFDD37F-6617-4944-B03A-954D5CAD0B30Q38038125-9C191DDC-88DC-456F-8A82-4F480C9BC447Q38195808-F98C197F-6DED-4BA8-90BC-E8A2B0D75E71Q38204183-4FF599D8-EA4C-4CDF-B677-530D2043C174Q38214386-69B31E2C-F53B-4740-9980-6CFABDA5D3B2Q38226897-435977D9-16B6-4711-A99D-AC43638B9064Q38235611-43762A4A-35A1-453C-A80B-6D296747D5B3Q38269470-974CFE5A-8301-412D-B0B7-158871ABD7F7Q38892210-FB23ED14-842C-4D35-872C-83018284D38BQ38969073-A70B6AA3-7344-4653-830D-38B5AAD36323Q41888381-03846CA8-3C79-4B24-94A8-06FA3556CFB0
P2860
A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@ast
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@en
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@nl
type
label
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@ast
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@en
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@nl
prefLabel
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@ast
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@en
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@nl
P2093
P356
P1476
A small-molecule inhibitor of ...... cokinetic, and safety profile.
@en
P2093
Bridget Cole
James Ellis
John Ferkany
Olivier Schueller
Paul Sweetnam
Stewart Campbell
P304
P356
10.1124/JPET.110.177527
P407
P577
2011-03-15T00:00:00Z